*BSC was administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, and other patient management approaches with palliative intent (excludes systemic antitumor therapy).1
†PD-L1 expression was assessed in tumor samples using the VENTANA PD-L1 (SP263) assay.1
BICR=blinded independent central review; CR=complete response; ECOG PS=Eastern Cooperative Oncology Group (ECOG) Performance Status; PD-L1=programmed death ligand-1; PR=partial response; RECIST=Response Evaluation Criteria in Solid Tumors; SD=stable disease.